Literature DB >> 8517714

Antimicrobial susceptibilities of enterococci isolated from hospitalized patients.

M Venditti1, A Tarasi, V Gelfusa, E Nicastri, A Penni, P Martino.   

Abstract

One hundred and one isolates of Enterococcus species isolated recently from hospitalized patients were evaluated in vitro for antibiotic susceptibility. Teicoplanin and mideplanin were the most active agents, followed by ramoplanin, vancomycin, ciprofloxacin, ampicillin, and imipenem. High-level resistance to gentamicin (MIC > 500 micrograms/ml) and/or streptomycin (MIC > 2,000 micrograms/ml) was found in 60 isolates. High-level resistance to ampicillin (MIC > or = 16 micrograms/ml) was found in 17 isolates. MBC studies revealed that ramoplanin possesses significant bactericidal activity.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8517714      PMCID： PMC187931          DOI： 10.1128/AAC.37.5.1190

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  21 in total

1.  Vancomycin-resistant enterococci.

Authors:  A H Uttley; C H Collins; J Naidoo; R C George
Journal:  Lancet       Date:  1988 Jan 2-9       Impact factor: 79.321

Review 2.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

3.  Synergistic treatment of enterococcal endocarditis: in vitro and in vivo studies.

Authors:  P Serra; C Brandimarte; P Martino; S Carlone; G Giunchi
Journal:  Arch Intern Med       Date:  1977-11

4.  Enterococci from Bangkok, Thailand, with high-level resistance to currently available aminoglycosides.

Authors:  B E Murray; J Tsao; J Panida
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

5.  High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections.

Authors:  L M Bush; J Calmon; C L Cherney; M Wendeler; P Pitsakis; J Poupard; M E Levison; C C Johnson
Journal:  Ann Intern Med       Date:  1989-04-01       Impact factor: 25.391

6.  Enterococci highly resistant to penicillin and ampicillin: an emerging clinical problem?

Authors:  F L Sapico; H N Canawati; V J Ginunas; D S Gilmore; J Z Montgomerie; W J Tuddenham; R R Facklam
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

7.  Bactericidal activity of ramoplanin against antibiotic-resistant enterococci.

Authors:  C C Johnson; S Taylor; P Pitsakis; P May; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

8.  High-level resistance to gentamicin in clinical isolates of enterococci.

Authors:  B D Mederski-Samoraj; B E Murray
Journal:  J Infect Dis       Date:  1983-04       Impact factor: 5.226

9.  Effects of medium and inoculum variations on screening for high-level aminoglycoside resistance in Enterococcus faecalis.

Authors:  D F Sahm; C Torres
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

10.  Enterococcal infections in patients treated with moxalactam.

Authors:  R C Moellering
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec
View more
  2 in total

1.  Characterization of vancomycin-resistant Enterococcus faecium isolates from the United States and their susceptibility in vitro to dalfopristin-quinupristin.

Authors:  G M Eliopoulos; C B Wennersten; H S Gold; T Schülin; M Souli; M G Farris; S Cerwinka; H L Nadler; M Dowzicky; G H Talbot; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 2.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.